BACKGROUND: Arformoterol tartrate (arformoterol, 15 m g bid) is a nebulized long-acting b 2 -agonist approved for maintenance treatment of COPD.
COPD is a common, preventable lung disease with treatable symptoms. 1 Airfl ow limitation is generally progressive and is partially reversible in most patients. 2, 3 Chronic airway and lung infl ammation contributes to progressive loss of lung function in aff ected individuals. Worldwide, COPD exacerbations and comorbidities are a major cause of morbidity and mortality, and are associated with a high economic and social burden. 1, 4, 5 Inadequate diagnosis and treatment of COPD are common, 6, 7 and may contribute to increased dyspnea, frequent exacerbations, deterioration of lung and physical function, and reduced quality of life (QoL). 1, 8 Major goals of COPD treatment include reducing symptoms, improving QoL, limiting exacerbations, and slowing loss of lung function. 1 Depending on disease severity, patients typically experience one to three exacerbations yearly 9 ; however, exacerbation prevalence may be substantially higher. 10, 11 Mortality (all-cause, lower respiratory, and cardiac) is higher among patients hospitalized for exacerbations. 12 Comorbidities associated with worse prognosis and lower QoL include cardiovascular disease, osteoporosis, anxiety/depression, lung cancer, infections, metabolic syndrome, and diabetes. 1 Long-acting bronchodilators may reverse airway hyperreactivity and bronchospasm in patients with asthma or COPD. Among bronchodilators, long-acting b -agonists (LABAs) have been associated with increased risk for exacerbation or death in patients with asthma [13] [14] [15] but not in patients with COPD, 16, 17 nor has LABA use been associated with undue risk of adverse events (AEs) in COPD. A review of 20 studies (N . 8,700) reported a low incidence of AEs and no association between LABA use and death, increased exacerbations, or COPD-related AEs. 16 A history of cardiovascular disease is common in patients with COPD 18 ; however, studies indicate comparable or somewhat lower rates of AEs, including cardiac AEs, with LABAs compared with placebo. [19] [20] [21] One exception is the potential for cardiac arrhythmias in elderly patients with cardiovascular disease. 22 Th e US Food and Drug Administration has asked manufacturers of LABAs indicated for COPD to evaluate risks in this patient population. Th is trial was conducted as a postapproval commitment to further evaluate the safety of arformoterol, especially the risk of life-threatening respiratory events, such as COPD exacerbations and respiratory death, over 1 year in patients with moderate to severe COPD. Arformoterol tartrate (arformoterol) is a selective LABA administered via nebulization that is approved in the United States for maintenance treatment of bronchoconstriction in patients with COPD. 23 Th ese fi ndings may provide clinicians with additional assurance of arformoterol safety and effi cacy in patients with moderate to severe COPD.
Materials and Methods

Patients
Patients were Ն 40 years of age with COPD, a Ն 15-pack-year smoking history, and baseline Modified Medical Research Council (MMRC) Dyspnea Scale Score Ն 2. Prebronchodilator FEV 1 of Յ 65% of predicted, FEV 1 . 0.50 L, and FEV 1 /FVC ratio of Յ 70% were also required. Patients were excluded for history of asthma (unless limited to childhood), life-threatening/unstable respiratory status including respiratory infection Յ 30 days before screening, change in COPD medications Յ 2 weeks before screening, or signs of infection Յ 72 h before screening. An independent data and safety monitoring board monitored the study on an ongoing basis. Th e study was conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines. Central/ local institutional review boards approved the protocol, and written informed consent was obtained from all patients. Additional information on the study and patients is available in e-Appendix 1 .
Study Design and Treatment
Th is was a multicenter, double-blind, randomized, placebo-controlled, parallel-group, outpatient study conducted at 71 clinical sites in the United States. Patients with moderate to severe COPD were randomized 1:1 to arformoterol or placebo (citrate-buff ered saline), each administered bid via nebulization ( Fig 1 ) . Participation consisted of six visits over about 1 year ( Fig 2 ) . All patients were to be followed for 1 year postrandomization. Maintenance COPD medications other than LABAs were continued throughout the study and patients were permitted rescue albuterol (Ventolin HFA) and supplemental ipratropium use Ն 6 h before visits. Disallowed medications and withholding periods for other long-acting bronchodilators (including tiotropium) are reported in e- Table 1 .
Assessments
Th e primary end point of this event-driven study was time from randomization to respiratory death or first COPD exacerbation-related hospitalization. Respiratory deaths were recorded when respiratory status was the primary or contributing cause of death determined by the principal investigator/medical monitor. Secondary end points included protocol-defi ned COPD exacerbations, mortality, AEs, and serious AEs (SAEs). Cardiac deaths were attributed similarly to respiratory deaths. Effi cacy assessments included change from baseline in spirometry and QoL measures (permission was obtained for use of the St. George's Respiratory Questionnaire [SGRQ]). Patients who discontinued study treatment were followed by phone for primary events for 1 year postrandomization ( e-Appendix 1 ).
Statistical Methodology
Th e statistical design was based on demonstrating noninferiority, defi ned as a Յ 40% higher risk (hazard ratio [HR] 1.4) of a primary event with arformoterol vs placebo. The study was powered under a one-sided alternative hypothesis, in which arformoterol was superior to placebo (HR Յ 0.80). Th e HR (90% CI) for the primary assessment was estimated using a Cox proportional hazards regression model, with treatment group, baseline smoking status, sex, age, BMI, and baseline FEV 1 as covariates. Other assessments are summarized descriptively ( e-Appendix 1 ).
Results
Patients
Patient demographics and baseline characteristics, including smoking status, MMRC dyspnea status, frequency of exacerbations, comorbid conditions, and types and frequency of medications used were evenly balanced between treatment groups ( Table 1 ) .
Disposition:
Overall, 45% of patients discontinued early from arformoterol (39.3%) or placebo (49.9%) treatment ( Fig 1 ) . Among those who discontinued, the majority discontinued arformoterol (51.5%) or placebo (60%) during the fi rst 3 months of treatment. Most discontinuations (19.0% and 27.6%, respectively) were based on patient decision (individual reasons not reported). Discontinuations because of an AE were reported by 13.1% Table 2 ). Sensitivity analyses were conducted to assess the eff ect of events recorded during the follow-up period after early treatment termination. Results were consistent for all sensitivity analyses ( e-Appendix 1 , Fig 4 ) .
Protocol-Defined COPD Exacerbations:
Protocoldefined COPD exacerbations (ie, increased COPD symptoms that necessitated any change in baseline medication) were reported by 122 patients (29%) receiving arformoterol and 132 patients (31.4%) receiving placebo. Approximately 17% of patients in each group reported one event; 6.9% and 8.1% of patients, respectively, reported two events; and 5.2% and 6.2%, respectively, reported at least three events. Risks for first protocol-defined COPD exacerbation (HR, 0.801; P 5 .078) and recurrent protocol-defi ned COPD exacerbation (HR, 0.768; P 5 .043) were lower with arformoterol than placebo.
Adverse Events: Patients receiving arformoterol or placebo had a similar incidence of AEs (72.9% vs 68.2%, respectively). Th e most frequently reported AE was an exacerbation or worsening of COPD (not protocoldefined), which was less commonly reported with arformoterol than placebo (23.3% vs 28.0% patients, respectively). Th e only nonrespiratory AEs occurring in Ն 5% of patients were headache, nausea, and urinary tract infection ( Table 3 ). Additional information on treatment-related AEs is available in e-Appendix 1 .
Deaths: Twelve patients (2.9%) receiving arformoterol and 10 patients (2.4%) receiving placebo died postrandomization. In the arformoterol group, two deaths were attributed to dual SAEs (cardiorespiratory arrest and squamous cell carcinoma in one patient; pneumonia and respiratory arrest in one patient). Additionally, two deaths were attributed to myocardial infarction and one each to COPD, cardiorespiratory arrest, respiratory failure, coronary artery disease, squamous cell carcinoma, brain neoplasia, head injury, and sepsis. Seven patients receiving placebo died of COPD, and one each from pneumonia, congestive heart failure, and lung cancer. 
Analysis of Time-to-First SAE:
Time-to-event analyses (defi ned as the time from randomization until the fi rst event onset date) were conducted for fi rst SAE, respiratory SAE, cardiac SAE, and AE resulting in discontinuation of study treatment. Risk for a fi rst respiratory SAE was about 50% lower with arformoterol than placebo (HR, 0.508; P 5 .003). Time-to-fi rst SAE and time-tofi rst AE resulting in discontinuation were numerically longer, whereas time-to-fi rst cardiac SAE was numerically shorter with arformoterol than placebo. No statistically signifi cant treatment diff erences were observed ( e-Appendix 1 , Table 5 ).
Results of clinical assessments, including laboratory fi ndings, vital signs, and ECG results are described in e-Appendix 1 .
Effi cacy
Lung Function: Arformoterol demonstrated greater improvements from baseline in lung function at 1 year vs placebo ( SAEs were defi ned as events with onset date occurring on or after the date of fi rst dose of double-blind study medication. Reports of SAEs were collected from the time of informed consent to 30 d after last scheduled dose. For patients who discontinued treatment before completing the study, primary events and other fatal events were collected up to 1 y after randomization. SAE 5 serious adverse event. See Table 1 legend for expansion of other abbreviations. were censored in the time-to-fi rst SAE analysis; therefore, n 5 81 and n 5 80 patients in the placebo and arformoterol arms, respectively. b Hazard ratio, 95% CI for the hazard ratio, and Wald test P value were from a Cox proportional hazards regression model for time-to-fi rst event with treatment group, baseline smoking status, sex, age, and baseline FEV 1 values as covariates.
(IC) from baseline was not significantly greater with arformoterol (LSM diff erence, 0.045 L; P 5 .125). Absolute mean values for change in FEV 1 were comparable to LSM values reported herein. See e-Appendix 1 and e- Table 2 for QoL assessments and rescue medication use.
Discussion
Th e primary objective of this phase 4 trial (ie, postapproval commitment) in patients with COPD was to determine whether long-term use of arformoterol was associated with fatal and life-threatening respiratory Table 1 legend for expansion of other abbreviations. a n 5 420 at baseline and overall. b Overall treatment eff ect from the repeated measures linear model for change from baseline with covariates for treatment, baseline smoking status, baseline IC, baseline IC-by-visit interaction, visit, and the treatment-by-visit interaction. P values were unadjusted for multiplicity. c n 5 416 at baseline and overall. events, which had been observed in studies of LABAcontaining products in patients with asthma. 14, 15, 24 In this study, arformoterol demonstrated an approximately 40% lower risk of respiratory death or COPD exacerbation-related hospitalization over 1 year vs placebo, suggesting that, in this study population, no such association was detected. Patients receiving arformoterol experienced fewer protocol-defi ned COPD exacerbations, fewer respiratory SAEs, and a signifi cantly lower risk (about 50%; P 5 .003) of a fi rst respiratory SAE vs placebo. Cardiac SAEs were numerically higher with arformoterol than placebo (HR, 1.059; P 5 .905). Arformoterol significantly improved QoL measures (SGRQ total score, Symptoms and Impacts individual scores, and Clinical COPD Questionnaire [CCQ] score) ( e- Fig 1 ) from baseline vs placebo. Improvements in lung function (ie, mean placebo-adjusted increase in trough FEV 1 of 51 mL) were consistent with those observed with other approved bronchodilators in a population with mostly severe airfl ow limitation who were receiving substantial background therapy. 25 Findings were consistent with previous studies demonstrating that arformoterol is an eff ective and tolerable COPD maintenance therapy, and no safety signal suggestive of drug-related, life-threatening respiratory or cardiac events was evident. 4, [26] [27] [28] Th e safety and effi cacy of LABAs and long-acting muscarinic antagonists in COPD have been demonstrated in several trials. Th e fi rst two trials were long-term "mega trials"-Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) (tiotropium) and Towards a Revolution in COPD Health (TORCH) (salmeterol/fl uticasone propionate combination). 29, 30 Although neither long-term trial achieved signifi cant primary outcomes (reduction in lung function decline over 4 years in UPLIFT or reduction in all-cause mortality aft er 3 years in TORCH), they demonstrated that long-acting bronchodilators reduce exacerbation rates and improve health status and QoL with no increased mortality risk or an excess of cardiac SAEs. An additional trial of note assessed the eff ect of triple therapy (budesonide/formoterol plus tiotropium) over 12 weeks. 31 Although this trial supports the administration of longacting bronchodilators in combination with inhaled corticosteroids (about 57% of current-study patients), its short duration does not permit defi nitive conclusions regarding long-term effi cacy and safety. Th e current 1-year study demonstrates the safety and effi cacy of arformoterol and provides reassurance that LABAs do not increase the risk of exacerbations or respiratory death in patients with COPD.
Study strengths include a large patient cohort with longterm treatment data. Importantly, 1-year effi cacy data for pulmonary function measures provide additional information on the eff ects of nebulized bronchodilator treatment against a background of naturally declining lung function. A noninferiority statistical design was used; however, arformoterol was superior to placebo based on an upper bound of the HR (90% RCI) point estimate of 0.606 (0.425, 0.864) being , 1.0 (null value of no treatment diff erence). Sensitivity analyses assessing the impact of treatment follow-up, important protocol deviations, and baseline covariates support the primary analysis that arformoterol did not increase the risk of respiratory death or COPD exacerbation-related hospitalizations vs placebo during 1 year of treatment.
Th ere were several study limitations. Th ere was a low baseline exacerbation rate of about one COPD exacerbation in the prior year (low-moderate risk). It is unclear what eff ect a lower baseline exacerbation rate would have on study outcomes. However, because sample size was driven by the number of primary events observed, the likely impact was only on the number of patients needed for enrollment. Other baseline characteristics (including percent-predicted FEV 1 of about 40%) indicate a population with fairly severe disease (based on GOLD [Global Initiative for Chronic Obstructive Lung Disease] guidelines in eff ect at study initiation). If patients in the current study were reassessed using the current GOLD evaluation criteria (eg, symptoms, exacerbation history, and exacerbation rates at baseline), one would expect a more complete picture of exacerbation risk, but not necessarily of mortality risk. Th ere were also a high number of patient withdrawals from treatment (but not withdrawals from study). Fortyfi ve percent of patients discontinued arformoterol (39.3%) and placebo (49.9%) during the study; however, among 841 randomized patients, only 89 (10.6%; 42 arformoterol, 47 placebo) were not followed for 1 year. Th e discontinuation rate is comparable to, albeit at the higher end of, the range observed in other long-term COPD studies (27%-44%). [28] [29] [30] Patient-initiated discontinuation was more common with placebo than arformoterol (a fi nding that may be related to lack of effi cacy, as has been discussed previously 32 ), although this was not assessed as an independent reason for withdrawal. Discontinuations occurred primarily during the first 3 months of treatment.
Th e eff ect of discontinuations on incidence of primary events was assessed in a sensitivity analysis ( e- Table 3 ). Specifi cally, how many events would need to occur in patients who discontinued vs patients who completed the trial to overturn the fi ndings for superiority and noninferiority of arformoterol? Th e incidence of the primary end point would have to be fi vefold higher (about 50% vs about 10%) in arformoterol dropouts than in completers to overturn the superiority fi nding, and . 20-fold higher to overturn the noninferiority fi nding. We believe that this analysis provides reassurance that the number of discontinuations postrandomization in this study would not aff ect our conclusions.
In conclusion, this long-term safety study demonstrates that arformoterol did not increase the risk of respiratory death or COPD exacerbation-related hospitalizations vs placebo during 1 year of treatment. Th ese results are consistent with fi ndings in the 3-year TORCH study that demonstrated the long-term safety of LABAs in patients with COPD. 29 In addition, patients receiving arformoterol experienced improvements in lung function and QoL measures vs patients receiving placebo.
